Gujarat Themis Biosyn (NSE:GUJTHEM) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GUJTHEM Gujarat Themis Biosyn Ltd NSE:GUJTHEM
65 GF Score
Price ₹372.30
GF Value ₹351.51
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Gujarat Themis Biosyn Marketable Securities?

Gujarat Themis Biosyn NSE:GUJTHEM +0.27% 65 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GUJTHEM with a GF Score™ of 65/100 and a GF Value™ of ₹351.51 (Fairly Valued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Gujarat Themis Biosyn's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Gujarat Themis Biosyn's annual Marketable Securities declined from Mar. 2024 (₹77 Mil) to Mar. 2025 (₹0 Mil) but then increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹33 Mil).

Gujarat Themis Biosyn  (NSE:GUJTHEM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Gujarat Themis Biosyn Marketable Securities Related Terms

Gujarat Themis Biosyn Marketable Securities Historical Data

* Premium members only.

The historical data trend for Gujarat Themis Biosyn's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Themis Biosyn Marketable Securities Chart

Gujarat Themis Biosyn Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.09 28.48 76.58 0.00 32.97

Gujarat Themis Biosyn Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 40.27 0.00 32.97 0.00
NSE:GUJTHEM
65GF Score
Gujarat Themis Biosyn Ltd NSE:GUJTHEM
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Themis Biosyn Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Gujarat Themis Biosyn (NSE:GUJTHEM) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Gujarat Themis Biosyn and its competitors.
Is Gujarat Themis Biosyn's Marketable Securities too high?
Gujarat Themis Biosyn's current Marketable Securities is ₹0 Mil. Overall, Gujarat Themis Biosyn has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's Marketable Securities compare to ZTS?
Gujarat Themis Biosyn's Marketable Securities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Gujarat Themis Biosyn and its competitors. Gujarat Themis Biosyn's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (NSE:GUJTHEM) is currently considered Fairly Valued. The stock's GF Value™ is ₹351.51, compared to a current price of ₹372.30 — trading 5.9% above its estimated fair value. The current Marketable Securities is ₹0 Mil. Gujarat Themis Biosyn's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Gujarat Themis Biosyn (NSE:GUJTHEM), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gujarat Themis Biosyn (NSE:GUJTHEM) Overvalued in 2026?

Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued. The current stock price of ₹372.30 is trading 5.9% above its estimated GF Value™ of ₹351.51. GuruFocus considers Gujarat Themis Biosyn to be Fairly Valued.

Key valuation signals for NSE:GUJTHEM:

  • Marketable Securities: ₹0 Mil
  • GF Value™: ₹351.51 vs. price of ₹372.30 (5.9% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the NSE:GUJTHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gujarat Themis Biosyn Business Description

Other Exchanges 506879:India
Address S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
65GF Score

Get the complete analysis for NSE:GUJTHEM

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹372.30
Price
₹351.51
GF Value